Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma

Tyler J D'Ovidio, Kathryn Ciccolini, Matko Kalac, Keren Osman, Amir Steinberg

Blood (2021) 138 (Supplement 1): 4811.

https://doi.org/10.1182/blood-2021-147586

Published: 2021

Journal Articles

Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)

Jieqi Liu, Epperla Narendranath, Armin Ghobadi, Aleksandr Lazaryan, Uroosa Ibrahim, Caron Jacobson, Seema G Naik, Adam J. Olszewski, Yong Lin, Sayan Mullick Chowdhury, Miriam T. Jacobs, Loretta Nastoupil, Keren Osman, Sairah Ahmed, Andrew M. Evens

Blood (2021) 138 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2021-149786

Published: 2021

Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Blood (2021) 138 (Supplement 1): 430.

https://doi.org/10.1182/blood-2021-147598

Published: 2021

Journal Articles

The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns

Anita D'Souza, MBBS, Keren Osman, MD, Cristiana Costa Chase, DO, Azah Borham, PharmD, Marianna Bruno, PharmD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-137740

Published: 2020

Journal Articles

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Larysa Sanchez, MD, Heather J Landau, MD, Cara A. Rosenbaum, MD, Alex Abrahams, Cindy Chin, Brielle Liotta, BS, Natalie Agudo, RN, Sheetal Ramnath, Elizabeth Hoover, BS, Hafsa Rahman, Umut Ozbek, PhD, Oscar B Lahoud, MD, Hani Hassoun, MD, Keren Osman, MD

Blood (2019) 134 (Supplement_1): 3128.

https://doi.org/10.1182/blood-2019-126023

Published: 2019

Journal Articles

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Galina G. Lagos, MD, Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey A Zonder, MD, Keren Osman, MD, Julia Gould, BA, Wei-Yann Tsai, PhD, Silva Pregja, MBA, Mariamne Reyna, BS, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 1838.

https://doi.org/10.1182/blood.V130.Suppl_1.1838.1838

Published: 2017

Journal Articles

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Keren Osman, MD, Ajai Chari, Samir Parekh, MD, Adolfo Aleman, Jessica Caro, MD, Gillian Morgan, RN, Erika Florendo, NP, Elaine Chan, Gina Strumolo, Katarzyna Zarychta, Lisa La, BS, MS, John Mandeli, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Sundar Jagannath, MD, Hearn Jay Cho, MD PhD

Blood (2017) 130 (Supplement 1): 3282.

https://doi.org/10.1182/blood.V130.Suppl_1.3282.3282

Published: 2017

Journal Articles

Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Keren Osman, MD, Ajai Chari, MD, Samir Parekh, MD, Christine Pun, BS, Gillian Morgan, RN, Erika Florendo, ANP-BC, Elaine Chan, BS, Marisa Shields, Gina Strumolo, MA, Lisa La, MS/CCRP, John Mandeli, PhD, James Geerlof, BS, PA, Sundar Jagannath, MD, Hearn Jay Cho, MD PhD

Blood (2016) 128 (22): 3448.

https://doi.org/10.1182/blood.V128.22.3448.3448

Published: 2016

Journal Articles

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

Galina Grigoriev Lagos, MD, Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey Zonder, MD, Keren Osman, MD, Julia Gould, BA, Wei-Yann Tsai, Silva Pregja, MBA, Mariamne Reyna, BS, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2016) 128 (22): 4523.

https://doi.org/10.1182/blood.V128.22.4523.4523

Published: 2016

Journal Articles

Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Jeffrey A Zonder, MD, Keren Osman, MD, Miao Susanna, Daniel Backenroth, Daniel Otap, Wei-Yann Tsai, Siva Pregja, Shahzad Raza, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD

Blood (2015) 126 (23): 3041.

https://doi.org/10.1182/blood.V126.23.3041.3041

Published: 2015

Journal Articles

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

Ajai Chari, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Keren Osman, MD, Talia Goldstein, BA, Gillian Morgan, Lisa La, MS/CCRP, Crystle Carter, RN, Donna Catamero, Juliet Escalon, Daniel Verina, Erika Florendo, Moon-hee Yum, RN, Nadege Stevens, RN, Jude Gullie, BA, Elaine Chan, BS, Sundar Jagannath, MD

Blood (2015) 126 (23): 3051.

https://doi.org/10.1182/blood.V126.23.3051.3051

Published: 2015

Journal Articles

Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis

Suzanne Lentzsch, MD PhD, Raymond L. Comenzo, MD, Keren Osman, MD, Kevin Zikaras, BS, Daniel Backenroth, Wei-Yann Tsai, Vaishali Sanchorawala, MD, Heather Landau, MD

Blood (2014) 124 (21): 3480.

https://doi.org/10.1182/blood.V124.21.3480.3480

Published: 2014

Journal Articles

A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma

Noa Biran, MD, Samira Shahnaz, MD, Sundar Jagannath, MD, Hearn J. Cho, MD, PhD, Keren Osman, MD, Samir Parekh, MD, Danielle Choi, RN, Katarzyna Garcia, MS, Donna Catamero, NP, Lisa La, MS, Jude Gullie, BA, Elaine Chan, BS, Ajai Chari, MD

Blood (2013) 122 (21): 5392.

https://doi.org/10.1182/blood.V122.21.5392.5392

Published: 2013

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Maria J. Nieto, MD, Eileen Scigliano, MD, Celia L. Grosskreutz, MD, Steven Fruchtman, MD, John Mascarenhas, MD, Keren Osman, MD, Adriana Malone, MD, Samuel Cytryn, Vesna Najfeld, PhD, Ronald Hoffman, MD, Luis Isola, MD

Blood (2011) 118 (21): 4534.

https://doi.org/10.1182/blood.V118.21.4534.4534

Published: 2011

Journal Articles

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, M.D., Cristina Gasparetto, MD, Keren Osman, MD, Kristy Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, OCN, Jennifer MacLean, RN, Diane Winans, Dominic Moore, PhD, John Strader, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2010) 116 (21): 1955.

https://doi.org/10.1182/blood.V116.21.1955.1955

Published: 2010

Journal Articles

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V L germ line gene use and clonal plasma cell burden

Raymond L. Comenzo, Yana Zhang, Carmen Martinez, Keren Osman, Guillermo A. Herrera

Blood (2001) 98 (3): 714–720.

https://doi.org/10.1182/blood.V98.3.714

Published: 2001

NARROW

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma

Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis

Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis

A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V L germ line gene use and clonal plasma cell burden

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only